Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children

Giovanni Di Perri, Haria Guasparri Di Perri, Geraldo Badona Monteiro, Stefano Bonora, Cornelia Hennig, Marco Cassatella, Rocco Micciolo, Sandro Vento, Stella Dusi, Dante Bassetti, Ercole Concia

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

In an open, randomized, controlled therapeutic trial, 56 children with cerebral malaria (CM) were randomly assigned to receive standard Quinine regimen with or without pentoxifylline (10 mg/kg/day by continuous intravenous infusion). Pentoxifylline exerted an inhibitory effect on the synthesis of tumor necrosis factor (TNF), a possible mediator of CM. The 26 children who received pentoxifylline had significantly shorter comas than controls (median, 6 vs. 46 h; P <.001). Pentoxifylline recipients showed a trend toward a lower mortality, with a borderline significant difference (P =.055). The better outcome in the pentoxifylline group was associated with a decline in TNF serum levels on the third day of treatment in a few subjects that was not seen in controls. While alternative or concurrent mechanisms of action may be of some relevance, larger double-blind trials are needed to determine whether pentoxifylline has a therapeutic role in CM.

Original languageEnglish
Pages (from-to)1317-1322
Number of pages6
JournalJournal of Infectious Diseases
Volume171
Issue number5
DOIs
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Cerebral Malaria
Pentoxifylline
Therapeutics
Tumor Necrosis Factor-alpha
Quinine
Coma
Intravenous Infusions
Randomized Controlled Trials
Mortality
Serum

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Di Perri, G., Di Perri, H. G., Monteiro, G. B., Bonora, S., Hennig, C., Cassatella, M., ... Concia, E. (1995). Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. Journal of Infectious Diseases, 171(5), 1317-1322. https://doi.org/10.1093/infdis/171.5.1317

Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. / Di Perri, Giovanni; Di Perri, Haria Guasparri; Monteiro, Geraldo Badona; Bonora, Stefano; Hennig, Cornelia; Cassatella, Marco; Micciolo, Rocco; Vento, Sandro; Dusi, Stella; Bassetti, Dante; Concia, Ercole.

In: Journal of Infectious Diseases, Vol. 171, No. 5, 1995, p. 1317-1322.

Research output: Contribution to journalArticle

Di Perri, G, Di Perri, HG, Monteiro, GB, Bonora, S, Hennig, C, Cassatella, M, Micciolo, R, Vento, S, Dusi, S, Bassetti, D & Concia, E 1995, 'Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children', Journal of Infectious Diseases, vol. 171, no. 5, pp. 1317-1322. https://doi.org/10.1093/infdis/171.5.1317
Di Perri G, Di Perri HG, Monteiro GB, Bonora S, Hennig C, Cassatella M et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. Journal of Infectious Diseases. 1995;171(5):1317-1322. https://doi.org/10.1093/infdis/171.5.1317
Di Perri, Giovanni ; Di Perri, Haria Guasparri ; Monteiro, Geraldo Badona ; Bonora, Stefano ; Hennig, Cornelia ; Cassatella, Marco ; Micciolo, Rocco ; Vento, Sandro ; Dusi, Stella ; Bassetti, Dante ; Concia, Ercole. / Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. In: Journal of Infectious Diseases. 1995 ; Vol. 171, No. 5. pp. 1317-1322.
@article{14b0cc6c26984d3d96af34e0d2beace0,
title = "Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children",
abstract = "In an open, randomized, controlled therapeutic trial, 56 children with cerebral malaria (CM) were randomly assigned to receive standard Quinine regimen with or without pentoxifylline (10 mg/kg/day by continuous intravenous infusion). Pentoxifylline exerted an inhibitory effect on the synthesis of tumor necrosis factor (TNF), a possible mediator of CM. The 26 children who received pentoxifylline had significantly shorter comas than controls (median, 6 vs. 46 h; P <.001). Pentoxifylline recipients showed a trend toward a lower mortality, with a borderline significant difference (P =.055). The better outcome in the pentoxifylline group was associated with a decline in TNF serum levels on the third day of treatment in a few subjects that was not seen in controls. While alternative or concurrent mechanisms of action may be of some relevance, larger double-blind trials are needed to determine whether pentoxifylline has a therapeutic role in CM.",
author = "{Di Perri}, Giovanni and {Di Perri}, {Haria Guasparri} and Monteiro, {Geraldo Badona} and Stefano Bonora and Cornelia Hennig and Marco Cassatella and Rocco Micciolo and Sandro Vento and Stella Dusi and Dante Bassetti and Ercole Concia",
year = "1995",
doi = "10.1093/infdis/171.5.1317",
language = "English",
volume = "171",
pages = "1317--1322",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children

AU - Di Perri, Giovanni

AU - Di Perri, Haria Guasparri

AU - Monteiro, Geraldo Badona

AU - Bonora, Stefano

AU - Hennig, Cornelia

AU - Cassatella, Marco

AU - Micciolo, Rocco

AU - Vento, Sandro

AU - Dusi, Stella

AU - Bassetti, Dante

AU - Concia, Ercole

PY - 1995

Y1 - 1995

N2 - In an open, randomized, controlled therapeutic trial, 56 children with cerebral malaria (CM) were randomly assigned to receive standard Quinine regimen with or without pentoxifylline (10 mg/kg/day by continuous intravenous infusion). Pentoxifylline exerted an inhibitory effect on the synthesis of tumor necrosis factor (TNF), a possible mediator of CM. The 26 children who received pentoxifylline had significantly shorter comas than controls (median, 6 vs. 46 h; P <.001). Pentoxifylline recipients showed a trend toward a lower mortality, with a borderline significant difference (P =.055). The better outcome in the pentoxifylline group was associated with a decline in TNF serum levels on the third day of treatment in a few subjects that was not seen in controls. While alternative or concurrent mechanisms of action may be of some relevance, larger double-blind trials are needed to determine whether pentoxifylline has a therapeutic role in CM.

AB - In an open, randomized, controlled therapeutic trial, 56 children with cerebral malaria (CM) were randomly assigned to receive standard Quinine regimen with or without pentoxifylline (10 mg/kg/day by continuous intravenous infusion). Pentoxifylline exerted an inhibitory effect on the synthesis of tumor necrosis factor (TNF), a possible mediator of CM. The 26 children who received pentoxifylline had significantly shorter comas than controls (median, 6 vs. 46 h; P <.001). Pentoxifylline recipients showed a trend toward a lower mortality, with a borderline significant difference (P =.055). The better outcome in the pentoxifylline group was associated with a decline in TNF serum levels on the third day of treatment in a few subjects that was not seen in controls. While alternative or concurrent mechanisms of action may be of some relevance, larger double-blind trials are needed to determine whether pentoxifylline has a therapeutic role in CM.

UR - http://www.scopus.com/inward/record.url?scp=0028912884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028912884&partnerID=8YFLogxK

U2 - 10.1093/infdis/171.5.1317

DO - 10.1093/infdis/171.5.1317

M3 - Article

VL - 171

SP - 1317

EP - 1322

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -